PMID- 26981139
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160316
LR  - 20201001
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2016
DP  - 2016
TI  - Effects of Cymbidium Root Ethanol Extract on Atopic Dermatitis.
PG  - 5362475
LID - 10.1155/2016/5362475 [doi]
LID - 5362475
AB  - Cymbidium has known antibacterial and antiedema activity and has been used as an 
      ingredient in cosmetics and fragrances. The effects of Cymbidium ethanol extract 
      (CYM) on allergic response and the underlying mechanisms of action have not been 
      reported. Therefore, the purpose of this study was to determine the effect of CYM 
      on allergic responses. Topical application of CYM was effective against 
      immunoglobulin E (IgE)/dinitrophenyl-conjugated bovine serum albumin- (DNP-BSA-) 
      induced degranulation of RBL-2H3 cells and anaphylaxis in ICR mice. An allergic 
      dermatitis-like mouse model was used to evaluate the therapeutic potential of CYM 
      in vivo. Continuous application of 2,4-dinitrochlorobenzene (DNCB) not only 
      induced dermatitis in ICR mice but also aggravated the skin lesioning. However, 
      the application of CYM decreased skin lesion severity, scratching behavior, and 
      IgE levels. In addition, CYM downregulated the expression of the proinflammatory 
      cytokines interleukin- (IL-) 4, IL-13, and tumor necrosis factor- (TNF-) alpha. 
      Studies of signal transduction pathways showed that CYM suppressed the 
      phosphorylation of spleen tyrosine kinase (Syk), an upstream molecule. It also 
      inhibited the phosphorylation of Akt, phospholipase C- (PLC-) gamma, and 
      mitogen-activated protein kinase kinase kinase (MEKK). These results indicate 
      that CYM may be effective in preventing and reducing allergic response and may 
      have therapeutic potential as an antiallergic agent in disorders such as atopic 
      dermatitis.
FAU - Kim, Wan-Joong
AU  - Kim WJ
AD  - Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device 
      Laboratory, College of Science and Technology, Yonsei University, Wonju 220-710, 
      Republic of Korea.
FAU - Cha, Hae-Sim
AU  - Cha HS
AD  - Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device 
      Laboratory, College of Science and Technology, Yonsei University, Wonju 220-710, 
      Republic of Korea.
FAU - Lee, Myung-Hun
AU  - Lee MH
AD  - Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device 
      Laboratory, College of Science and Technology, Yonsei University, Wonju 220-710, 
      Republic of Korea.
FAU - Kim, Sun-Young
AU  - Kim SY
AD  - Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device 
      Laboratory, College of Science and Technology, Yonsei University, Wonju 220-710, 
      Republic of Korea.
FAU - Kim, Seo Ho
AU  - Kim SH
AD  - Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device 
      Laboratory, College of Science and Technology, Yonsei University, Wonju 220-710, 
      Republic of Korea.
FAU - Kim, Tack-Joong
AU  - Kim TJ
AD  - Division of Biological Science and Technology, Yonsei-Fraunhofer Medical Device 
      Laboratory, College of Science and Technology, Yonsei University, Wonju 220-710, 
      Republic of Korea.
LA  - eng
PT  - Journal Article
DEP - 20160211
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
PMC - PMC4766334
EDAT- 2016/03/17 06:00
MHDA- 2016/03/17 06:01
PMCR- 2016/02/11
CRDT- 2016/03/17 06:00
PHST- 2015/11/24 00:00 [received]
PHST- 2016/01/07 00:00 [revised]
PHST- 2016/01/14 00:00 [accepted]
PHST- 2016/03/17 06:00 [entrez]
PHST- 2016/03/17 06:00 [pubmed]
PHST- 2016/03/17 06:01 [medline]
PHST- 2016/02/11 00:00 [pmc-release]
AID - 10.1155/2016/5362475 [doi]
PST - ppublish
SO  - Evid Based Complement Alternat Med. 2016;2016:5362475. doi: 10.1155/2016/5362475. 
      Epub 2016 Feb 11.